Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial: European Journal of Cancer

G. Rosati, S. Lonardi, F. Galli, M. Di Bartolomeo, M. Ronzoni, M.G. Zampino, M. Banzi, A. Zaniboni, F. Pasini, S. Bozzarelli, S.K. Garattini, D. Ferrari, V. Montesarchio, A. Mambrini, L. Ciuffreda, V. Pusceddu, C. Carlomagno, P. Bidoli, D. Amoroso, A.M. BochicchioL. Frassineti, D. Corsi, D. Bilancia, A. Pastorino, A. De Stefano, R. Labianca

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Previous studies on oxaliplatin and fluoropyrimidines as adjuvant therapy in older patients with stage III colon cancer (CC) produced conflicting results. Patients and methods: We assessed the impact of age on time to tumour recurrence (TTR), disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) in 2360 patients with stage III CC (1667 aged
Original languageEnglish
Pages (from-to)190-201
Number of pages12
JournalEur. J. Cancer
Volume148
DOIs
Publication statusPublished - 2021

Keywords

  • Adjuvant chemotherapy
  • Colon cancer
  • Compliance
  • Older patients
  • Oxaliplatin
  • Prognostic factors
  • capecitabine plus oxaliplatin
  • fluoropyrimidine
  • oxaliplatin
  • adjuvant therapy
  • adult
  • aged
  • Article
  • cancer specific survival
  • cancer staging
  • colon cancer
  • controlled study
  • disease free survival
  • drug efficacy
  • female
  • follow up
  • human
  • major clinical study
  • male
  • overall survival
  • patient compliance
  • post hoc analysis
  • priority journal
  • treatment interruption
  • tumor recurrence

Fingerprint

Dive into the research topics of 'Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial: European Journal of Cancer'. Together they form a unique fingerprint.

Cite this